Pinnacle Financial Partners Inc Has $31.11 Million Stake in AbbVie Inc. (NYSE:ABBV)

Pinnacle Financial Partners Inc trimmed its position in shares of AbbVie Inc. (NYSE:ABBV - Free Report) by 1.0% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 173,978 shares of the company's stock after selling 1,676 shares during the quarter. AbbVie accounts for 0.6% of Pinnacle Financial Partners Inc's investment portfolio, making the stock its 29th largest holding. Pinnacle Financial Partners Inc's holdings in AbbVie were worth $31,106,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Capital City Trust Co. FL raised its position in AbbVie by 1.0% in the 4th quarter. Capital City Trust Co. FL now owns 36,988 shares of the company's stock valued at $6,573,000 after buying an additional 377 shares during the last quarter. Redmond Asset Management LLC bought a new position in AbbVie in the 4th quarter valued at $1,623,000. Oxbow Advisors LLC grew its stake in AbbVie by 1.3% in the 4th quarter. Oxbow Advisors LLC now owns 7,120 shares of the company's stock valued at $1,265,000 after purchasing an additional 88 shares during the period. Element Wealth LLC grew its stake in AbbVie by 1.4% in the 4th quarter. Element Wealth LLC now owns 5,405 shares of the company's stock valued at $960,000 after purchasing an additional 77 shares during the period. Finally, Prentice Wealth Management LLC grew its stake in AbbVie by 3.1% in the 4th quarter. Prentice Wealth Management LLC now owns 6,267 shares of the company's stock valued at $1,114,000 after purchasing an additional 190 shares during the period. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Stock Performance

Shares of NYSE ABBV opened at $202.03 on Friday. The stock has a market cap of $356.64 billion, a price-to-earnings ratio of 84.18, a P/E/G ratio of 1.58 and a beta of 0.58. The company has a current ratio of 0.66, a quick ratio of 0.54 and a debt-to-equity ratio of 17.94. AbbVie Inc. has a 1-year low of $153.58 and a 1-year high of $207.32. The stock's 50-day moving average is $180.68 and its 200 day moving average is $186.29.

AbbVie (NYSE:ABBV - Get Free Report) last announced its quarterly earnings data on Friday, January 31st. The company reported $2.16 earnings per share for the quarter, missing analysts' consensus estimates of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same period in the previous year, the firm earned $2.79 EPS. On average, sell-side analysts anticipate that AbbVie Inc. will post 12.32 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Investors of record on Tuesday, April 15th will be given a dividend of $1.64 per share. The ex-dividend date is Tuesday, April 15th. This represents a $6.56 annualized dividend and a yield of 3.25%. AbbVie's payout ratio is 273.33%.

Insider Buying and Selling

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the firm's stock in a transaction that occurred on Monday, December 16th. The stock was sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This trade represents a 20.49 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.25% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

ABBV has been the subject of a number of recent analyst reports. Truist Financial upped their price objective on AbbVie from $211.00 to $217.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Citigroup increased their price target on AbbVie from $205.00 to $215.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Piper Sandler Companies reiterated an "overweight" rating and set a $220.00 price target on shares of AbbVie in a research note on Tuesday, December 17th. Bank of America reiterated a "neutral" rating and set a $191.00 price target on shares of AbbVie in a research note on Tuesday, December 10th. Finally, Leerink Partnrs upgraded AbbVie from a "hold" rating to a "strong-buy" rating in a research note on Friday, November 22nd. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $208.35.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.